July 9, 2012
Press Release: FDA introduces new safety measures for extended-release and long-acting opioid medications
Questions and Answers: FDA approves a Risk Evaluation and Mitigation Strategy (REMS) for Extended-Release and Long-Acting (ER/LA) Opioid Analgesics
June 22, 2012
Acceptance of Naltrexone by Pregnant Women Enrolled in Comprehensive Drug Addiction Treatment: An Initial Survey By: Hendree E. Jones, PhD
June 14, 2012
Mental Illness in Teens Linked to Long-term Opioid Use, By: Joe Barber Jr, PhD
May 24, 2012
Cautious, Evidence-Based Opioid Prescribing: Physicians for Responsible Opioid Prescribing
May 15, 2012
Annals of Internal Medicine: Federal Plan for Prescriber Education on Opioids Misses Opportunities
May 10, 2012
Two New Resources to Curb Prescription Drug Abuse, By: Bret Stetka, MD; Elinore F. McCance-Katz, MD, PhD
April 18, 2012
PCSS-B Project Update
March 5, 2012
CESAR Report Warns of Emerging Epidemic of Buprenorphine Misuse
February 11, 2012
SAMHSA announces “An Introduction to Extended-Release Injectable Naltrexone for the Treatment of People With Opioid Dependence,” Advisory, Volume 11, Issue 1. This Advisory provides an overview of extended-release injectable naltrexone (Vivitrol), a treatment for people with opioid dependence. The Advisory will help behavioral health professionals and medical healthcare providers:
Access information about extended-release injectable naltrexone.
Compare extended-release injectable naltrexone’s features with those of other medication-assistance treatment options (e.g., methadone and buprenorphine).
Consider clinical strategies in selecting, initiating, and administering treatment.
The Advisory is a bulletin that provides behavioral health providers and others with information on emerging issues and hot topics that have immediate consequences for those in the behavioral health field.
“An Introduction to Extended-Release Injectable Naltrexone for the Treatment of People With Opioid Dependence,” Advisory, Volume 11, Issue 1 (SMA) 12-4682
February 6, 2012
Vermont Treatment Guidelines Regarding Treatment of Opioid Dependence During Pregnancy
Prior to 2012
Did You Give Up Your Waiver Because You Weren't Ready to Prescribe? Interested in Getting Your Waiver Reinstated?
How to Prepare for a Visit from the Drug Enforcement Administration (DEA) Regarding Buprenorphine Prescribing.